The Data from Phase 2a Tells a Story... The graph on the left shows the plot of changes in the MMSE scores (cognition) over 148 weeks of Phase 2a and the Open-Label Extension. Because the graph values include MMSE scores, Standard Error, and n, we can calculate Standard Deviation to arrive at Cohen's d Effect … Continue reading Cohen’s d Effect Size And Time In The Trials for Alzheimer’s Drug Blarcamesine And Why Results Come In The Second Half of 2024 $AVXL $SAVA
Beware of Lower ADAS-Cog11 Baseline Scores When Compaing Drug Performance Blarcamesine vs. Simufilam $AVXL $SAVA
The Nature of Neurodegenerative Diseases In general, these diseases are a constant struggle between the adaptive capability of the brain to injury and the process of neuronal death or impairment. The greater the progress of the disease the lesser the margin by which the adaptation or plasticity of the brain can cope with the devastation … Continue reading Beware of Lower ADAS-Cog11 Baseline Scores When Compaing Drug Performance Blarcamesine vs. Simufilam $AVXL $SAVA
$SAVA Has Reached The Extreme in Pursuit of Efficacy.
The Easiest Way to Prove Efficacy Is To ..... Select your subjects with so mild symptoms of Alzheimer's that even a minimal amount of therapeutic effect can move the needle. That is because the disease starts decimating the neurons in the patient's brain probably a decade before and the plasticity of the brain compensates for … Continue reading $SAVA Has Reached The Extreme in Pursuit of Efficacy.
Why You Won’t See The Full Phase 2b/3 Data Any Time Soon.
This Blog Is Only For Educational Purposes. Do Not Trade On This Blog Alone. Do Your Due Diligence or Consult a Professional. I have recently listened to the interview with Dr. Grimmer by @MayoMobile. The interview is on the Youtube channel The Spirit of the Coast Analytics. To open our discussion of the full Phase … Continue reading Why You Won’t See The Full Phase 2b/3 Data Any Time Soon.
Synthetic Odds Ratios in Phase 2a and Phase 2b/3 in Alzheimer’s Trial for Blarcamesine $AVXL
Lately, I have been posting videos but there ia limited capability of videos to disseminate graphics or plots. I decided to do a post and video later. The Anavex's data release on the results of Phase 2b/3 included Odds Ratio versus Placebo arm for cognition (MMSE) and Activities of Daily Living (ADCS-ADL). Again, we assume … Continue reading Synthetic Odds Ratios in Phase 2a and Phase 2b/3 in Alzheimer’s Trial for Blarcamesine $AVXL
How The Assuption That All Drugs Should Follow Normal Distribution Has Failed Anavex But Blarcamesien Has Succeeded.
Current Investor's Sentiment Dr Missling, notwithstanding the mishapps with data, has provided two sets of data relevant to investors. The first set consisted of the Means for both Placebo Cohort and the Combined Dosed Cohorts, their respectful Standard Deviations and Standard Errors which then were used to calculate the p-values. The sampling size n was … Continue reading How The Assuption That All Drugs Should Follow Normal Distribution Has Failed Anavex But Blarcamesien Has Succeeded.
Why Placebo Arm Is Critical To Proper Assesment Of Therapeutic Effect In Trials Of Alzheimer’s Disease. The Case of Phase2b/3 For Blarcamesine (Anavex2-73) And Simufilam Open Label. $AVXL $SAVA
The following post is in reference to paper tilted: link: https://alz-journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2010.03.018 The purpose of this paper is to establish realtionship between covariates like baseline severity, age, APOE4 genotype and gender, and the slope of yearly decline in ADAS-Cog cognition measure. The Conclusions Most Relevant To Investors: The mean slope is dependent mostly on baseline severity … Continue reading Why Placebo Arm Is Critical To Proper Assesment Of Therapeutic Effect In Trials Of Alzheimer’s Disease. The Case of Phase2b/3 For Blarcamesine (Anavex2-73) And Simufilam Open Label. $AVXL $SAVA
Looking To Release Of Information On 50mg Cohort Performance In Phase2b/3. $AVXL Blarcamesine
Let's get down to the nitty gritty of Due Diligence The fact that Phase2b/3 included 30mg cohort makes it just greater n Phase2a? If this question can be aswered in affirmitive than one would expect the 30mg follow placebo, or at least expect most of the responders to reside in the 50mg cohort. Notwithstanding the … Continue reading Looking To Release Of Information On 50mg Cohort Performance In Phase2b/3. $AVXL Blarcamesine
Anavex Life Sciences Phase2a For Alzheimer’s Vindicated with 509 Sample Size Phase2b/3. Blarcamesine $AVXL
Late Means Late The presented data has been just released to Anavex and processed to be delivered just in nick of time to Dr. Farlane to be presented at CTAD 2022. Unfortunately, I had not saved the presentation slides as I initially downloaded them and they have been remoed now. If anybody has a copy … Continue reading Anavex Life Sciences Phase2a For Alzheimer’s Vindicated with 509 Sample Size Phase2b/3. Blarcamesine $AVXL
Final Prognostication Before December 1, 2022 CTAD San Francisco Presentation.
Refined Illustration For Possible Performance of Blarcamesine On The Background of Donezepil, Simufilam and Donezepil Placebo, All Imperfect Comparison First thing is to point to a mistaken plus sign of the Avg. Delta ADAS-COG11, which should be -7.21, not 7.21. Green Line represents the performance of Donezepil Placebo from Donezepil Label Fig.2. But this is … Continue reading Final Prognostication Before December 1, 2022 CTAD San Francisco Presentation.